Cancer Gene Therapy Market: Market Size & Forecast 2026

Cancer gene therapy involves the introduction, removal, or alteration of genetic material within a patient's cells to treat cancer. The market has evolved rapidly from a niche research field to a commercially significant segment of the biotechnology industry. With annual growth rates near 20%, it represents one of the fastest-growing categories within the broader oncology therapeutics market.

• •Market valued at approximately $4.09 billion in 2025 with projected CAGR of 19% through 2035
• •Includes therapy types such as CAR-T cell therapy, oncolytic viruses, gene-induced immunotherapy, and RNAi-based treatments
• •Initially focused on hematological cancers, the field is expanding toward solid tumor applications

The market expansion is primarily fueled by the commercial success and increasing adoption of CAR-T cell therapies for blood cancers such as large B-cell lymphoma and multiple myeloma. Favorable regulatory environments and accelerated approval pathways have enabled more gene therapy products to reach the market. Growing cancer prevalence worldwide, coupled with rising healthcare expenditure and demand for personalized treatment options, further underpins demand.

• •Proven efficacy of CAR-T therapies in hematological malignancies is driving clinical adoption and pipeline investment
• •Regulatory agencies have established frameworks supporting accelerated approval for advanced therapy medicinal products
• •Increasing cancer incidence and aging global populations are expanding the addressable patient population

The market is segmented by therapy type into categories such as CAR-T cell therapy, tumor suppressor gene therapy, oncolytic virotherapy, and RNAi or miRNA-based therapies. North America currently dominates the market due to advanced healthcare infrastructure, strong R&D activity, and early regulatory approvals, while Europe and the Asia-Pacific region represent significant and rapidly growing markets.

• •CAR-T cell therapy constitutes the largest and most established segment within the market
• •North America leads in market share, supported by major biopharmaceutical R&D centers and favorable reimbursement policies
• •Asia-Pacific is expected to register the fastest regional growth, driven by increasing healthcare access and clinical trial activity

What are the recent trends and outlook?

Gene editing technologies such as CRISPR-Cas9 are expected to unlock new capabilities in cancer treatment, enabling more precise and durable therapeutic outcomes. The industry is gradually shifting from allogeneic to autologous approaches and exploring combination therapies to enhance efficacy against solid tumors. Manufacturing scalability and cost reduction remain critical focus areas as the market moves toward broader patient access.

• •CRISPR and other gene editing platforms are advancing into clinical trials for cancer indications, promising next-generation treatments
• •Development of allogeneic or off-the-shelf CAR-T products aims to reduce costs and improve treatment accessibility
• •Combination regimens pairing gene therapy with checkpoint inhibitors or other modalities are emerging as a key clinical strategy